Hepatic oncology (BCLC)

Featured projects

Epithelioid Hemangioendothelioma International Network

Principal investigator: Jordi Rimola, María Reig Monzón.
Funder: European Association for the Study of the Liver - EASL .

Code: EHIN.

Duration: 01/06/2021 - 01/06/2026

Summary:
Project Title: Epithelioid Hemangioendothelioma International Network Project reference: N/A PI: Jordi Rimola Funding Agency: EASL Funding: 50000 eur Duration: 2021-2026
A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology

Principal investigator: Jordi Rimola Gibert, Aleix Prat Aparicio.
Funder: European Commission .

Code: CE_H2020_SC1_20_1s13.

Duration: 01/10/2020 - 30/09/2024
"Improving immunotherapy in hepatocellular carcinoma via PD-1-TGFβ cotargeting"

Principal investigator: María Reig Monzón.
Funder: CIBEReHD .

Code: 20PI04.

Duration: 02/04/2020 - 01/04/2022

Summary:
Proyecto Competitivo Ciber.
Importancia del inflamasoma en la sensibilidad o resistencia a los inhibidores tirosina quinasa en pacientes con cáncer de hígado (PI18/00358) ( Importance of the inflammasome in the sensitivity or resistance to tyrosine kinase inhibitors in patients with

Principal investigator: María Reig Monzón.
Funder: Instituto de Salud Carlos III .

Duration: 01/01/2019 - 31/12/2022
Rendimiento de la RM con ácido gadoxético para el diagnóstico y estadiaje del carcinoma hepatocelular

Principal investigator: Alejandro Forner Gonzalez.
Funder: Instuto de Salud Carlos III ; Hospita Clinic de Barcelona (Sede o evento).

Code: PI18/00542.

Duration: 01/01/2019 - 31/12/2021
AECC Clínico 2018: Prospective clinical evaluation of the genetic-immuno / inflammatory profile in the treatment of hepatocellular carcinoma with sorafenib to predict tolerance and survival"

Principal investigator: Alvaro Díaz González, María Reig Monzón.
Funder: Asociación Española Contra el Cáncer (AECC). ; Asociación Española Contra el Cáncer (AECC) .

Code: CLJUN18016DIAZ.

Duration: 01/08/2018 - 31/12/2019
A phase I open label, clinical trial evaluating the safety and anti-tumor activity of autologous T cells expressing enhanced TCRS specific for alpha-fetoprotein (AFP C332T) in HLA-A2 positive subjects with advanced hepatocellular carcinoma (HCC).

Principal investigator: Jordi Bruix Tudo.
Funder: Adaptimmune .

Code: ADP-0033-001.

Duration: 01/01/2018 - 31/12/2033
La inhibición de miR122 como evento precoz en el desarrollo de carcinoma hepatocelular en pacientes infectados por el virus de la hepatitis C. Papel de miR122 en el sistema inmunitario.

Principal investigator: Loreto Boix Ferrero, Jordi Bruix Tudo.
Funder: Instituto de Salud Carlos III (ISCIII) .

Code: PI18/00768.

Duration: 01/01/2018 - 31/03/2022
Analysis of potential changes in antitumor immune activity in patients with hepatocellular carcinoma after C virus erradication with direct antiviral agents (GLD/00095)

Principal investigator: Mercedes Iñairraraegui, María Reig Monzón.
Funder: Gilead Sciences, S.L .

Duration: 01/01/2017 - 01/01/2019
Evaluación clínica prospectiva del perfil genético-inmuno/ inflamatorio en el tratamiento del carcinoma hepatocelular con sorafenib para predecir tolerancia y supervivencia-PI15/00145

Principal investigator: María Reig Monzón.
Funder: Instituto de Salud Carlos III .

Duration: 01/01/2016 - 01/01/2018

The research of this group can be carried out thanks to the funders.

Featured projects

Epithelioid Hemangioendothelioma International Network

A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology

"Improving immunotherapy in hepatocellular carcinoma via PD-1-TGFβ cotargeting"

Importancia del inflamasoma en la sensibilidad o resistencia a los inhibidores tirosina quinasa en pacientes con cáncer de hígado (PI18/00358) ( Importance of the inflammasome in the sensitivity or resistance to tyrosine kinase inhibitors in patients with

Rendimiento de la RM con ácido gadoxético para el diagnóstico y estadiaje del carcinoma hepatocelular

AECC Clínico 2018: Prospective clinical evaluation of the genetic-immuno / inflammatory profile in the treatment of hepatocellular carcinoma with sorafenib to predict tolerance and survival"

A phase I open label, clinical trial evaluating the safety and anti-tumor activity of autologous T cells expressing enhanced TCRS specific for alpha-fetoprotein (AFP C332T) in HLA-A2 positive subjects with advanced hepatocellular carcinoma (HCC).

La inhibición de miR122 como evento precoz en el desarrollo de carcinoma hepatocelular en pacientes infectados por el virus de la hepatitis C. Papel de miR122 en el sistema inmunitario.

Analysis of potential changes in antitumor immune activity in patients with hepatocellular carcinoma after C virus erradication with direct antiviral agents (GLD/00095)

Evaluación clínica prospectiva del perfil genético-inmuno/ inflamatorio en el tratamiento del carcinoma hepatocelular con sorafenib para predecir tolerancia y supervivencia-PI15/00145

Major founders